US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,852.12

-14.2693-0.50%

Number of Gainers:2

Number of Losers:3

Number of Flat:- -

PE:- -

High:2,866.51

Open:2,865.88

Low:2,790.25

Close:2,866.39

Volume:7.81M

Turnover:189.93M

Market Cap:45.58B

Float Cap:42.56B

Loading ...

Dare Bioscience - Files for Resale of up to 8,934,345 Shares of Common Stock - SEC Filing

THOMSON REUTERS

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Daré Bioscience Posts Phase 1 Data Showing Topical Sildenafil Cream Well Tolerated in Postmenopausal Women

Teva Pharmaceutical Rocked by Eye-Catching Insider Stock Moves

Daré Bio CEO Flags Ovaprene Interim Phase 3 Results as Potential Catalyst in Investor Interview

Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA

Simply Wall St.

MannKind Corporation - Selling Stockholders May Offer up to 12,853,470 Shares Including 2,412,632 Warrant Shares - SEC Filing

THOMSON REUTERS

Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate

Simply Wall St.

TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer

Femasys announces FDA approval of FemBloc modular premarket approval application

Teva Pharmaceuticals Says FDA Accepts Ecopipam Filing for Tourette Syndrome

MT Newswires Live

Femasys Says FDA OKs Modular PMA Pathway for FemBloc Birth Control Device

Femasys - FDA Approves Modular Pma Pathway for Fembloc in the United States

THOMSON REUTERS

Femasys - Fembloc Approved for Marketing in Europe and Select International Markets

THOMSON REUTERS

Daré Bioscience DARE-HPV Program Advances with Non-Dilutive US Government Funding

DarÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 over 50: Innovation” List

THOMSON REUTERS

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

Veru Chief Scientific Officer Gary Barnette Acquires $4,841.82 in Common Shares

Daré Bioscience Prices USD 6 Million Registered Direct Offering at USD 1.37 Per Share

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://nz.tigermarketb.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2852.123,"timestamp":1787774399999,"preClose":2866.3923,"halted":0,"volume":7814688,"delay":0,"changeRate":-0.004978,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-14.269287,"latestTime":"08-26 16:00:00 EDT","open":2865.882,"high":2866.507,"low":2790.2515,"amount":189931845.279611,"amplitude":0.026603,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787788800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.756212,"peRate":70.963025,"turnoverRate":0.005439,"increases":2,"decrements":3,"flats":0,"marketCap":45578633768,"floatMarketCap":42562171718},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2866.507,"amplitude":0.026603,"preClose":2866.3923,"low":2790.2515,"pbRate":"5.756212","latestPrice":2852.123,"volume":7814688,"delay":0,"open":2865.882,"prevYearClose":2379.9924,"prevWeekClose":2809.5261,"prevMonthClose":2636.2712,"prevQuarterClose":2562.5076,"fiveDayClose":2826.018,"twentyDayClose":2613.1003,"sixtyDayClose":2585.0193,"secType":"PLATE","market":"US","turnoverRate":0.005439,"peRate":70.963025,"marketCap":45578633768,"floatMarketCap":42562171718,"timestamp":1787774399999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":2,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662974784","title":"Dare Bioscience - Files for Resale of up to 8,934,345 Shares of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662974784","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662974784?lang=en_us&edition=fundamental","pubTime":"2026-08-27 05:16","pubTimestamp":1787779004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N11R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4007","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662171422","title":"Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations","url":"https://stock-news.laohu8.com/highlight/detail?id=2662171422","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662171422?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:00","pubTimestamp":1787749200,"startTime":"0","endTime":"0","summary":"-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug.  26, 2026 (GLOBE NEWS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351390/0/en/femasys-partners-with-unc-health-to-introduce-its-femaseed-fertility-portfolio-across-statewide-ob-gyn-care-locations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FEMY","BK4539","BK4082","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662711272","title":"Daré Bioscience Posts Phase 1 Data Showing Topical Sildenafil Cream Well Tolerated in Postmenopausal Women","url":"https://stock-news.laohu8.com/highlight/detail?id=2662711272","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662711272?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:45","pubTimestamp":1787748327,"startTime":"0","endTime":"0","summary":"Daré Bioscience posts Phase 1 data showing topical sildenafil cream well tolerated in postmenopausal womenDaré Bioscience disclosed publication of Phase 1 results for its topical sildenafil cream in h","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL9Ngst1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","NDAQ","LU2210149790.SGD","LU0314104364.USD","BK4584","LU2210150020.SGD","IE00BKPKM429.USD","BK4007","SG9999014021.USD","BK4585","IE00BN0W2W23.USD","IE00BQXX3F31.USD","IE00B64PRP62.GBP","BK4588","SG9999014013.SGD","BCDF","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR","DARE","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662769502","title":"Teva Pharmaceutical Rocked by Eye-Catching Insider Stock Moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2662769502","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662769502?lang=en_us&edition=fundamental","pubTime":"2026-08-26 10:03","pubTimestamp":1787709792,"startTime":"0","endTime":"0","summary":"New insider activity at Teva Pharmaceutical ( ($TEVA) ) has taken place on August 25, 2026. Recent insider activity at Teva Pharmaceutical has draw...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/teva-pharmaceutical-rocked-by-eye-catching-insider-stock-moves-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/teva-pharmaceutical-rocked-by-eye-catching-insider-stock-moves-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4557","BK4588","BK4566","BK4007","BK4596","LU1983299246.USD","TEVA","BK4584","LU2324357040.USD","BK4559","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662724732","title":"Daré Bio CEO Flags Ovaprene Interim Phase 3 Results as Potential Catalyst in Investor Interview","url":"https://stock-news.laohu8.com/highlight/detail?id=2662724732","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662724732?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:55","pubTimestamp":1787662519,"startTime":"0","endTime":"0","summary":"Daré Bio CEO flags Ovaprene interim Phase 3 results as potential catalyst in investor interviewDaré Bioscience management outlined its shift from development-stage to commercial-stage in a Virtual Inv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL4Scn4d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU0314104364.USD","SG9999014021.USD","NDAQ","LU2095319765.USD","SG9999014039.USD","BK4584","IE00B64PRP62.GBP","BK4007","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","DARE","IE00BN0W2W23.USD","LU2210149790.SGD","BK4588","IE00BQXX3C00.GBP","BCDF","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","BK4585","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732058","title":"Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732058?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:55","pubTimestamp":1787662500,"startTime":"0","endTime":"0","summary":"President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value ove","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","MEDX","BK4585","GDOC","HYLG","BK4604","BK4555","IDNA","BK4007","03160","BK4099","TM","BK4588","LABU","DARE","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662581730","title":"Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662581730","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662581730?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:28","pubTimestamp":1787660886,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, an investigational pediatric Tourette syndrome treatment with Orphan Drug status.\nSee our latest analysis for Teva Pharmaceutical Industries.\nThe ecopipam news lands after a strong run for Teva Pharmaceutical Industries, with a 30 day share price return of 19.86% and a 1 year total shareholder return of 103.81% that signals building momentum...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-10-undervalued","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-10-undervalued","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1983299246.USD","LABU","TEVA","LU2324357040.USD","BK4588","BK4596","BK4559","BK4566","BK4585","BK4584","BK4557","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661529765","title":"MannKind Corporation - Selling Stockholders May Offer up to 12,853,470 Shares Including 2,412,632 Warrant Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2661529765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661529765?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:07","pubTimestamp":1787342833,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNKD","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660633238","title":"Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2660633238","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660633238?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:30","pubTimestamp":1787232636,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries (NYSE:TEVA) announced that the U.S. FDA has accepted its New Drug Application for ecopipam for pediatric Tourette syndrome with Priority Review status.\nEcopipam is described by Teva as a first in class therapy candidate targeting children and adolescents with Tourette syndrome, an area where no new treatments have been approved in over a decade.\nThe filing is backed by positive late stage clinical trial data and adds another potential branded medicine to Teva's...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-teva-wins-fda-priority-review-for-pediatric-tourette-dr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-teva-wins-fda-priority-review-for-pediatric-tourette-dr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4596","LABU","BK4566","BK4588","LU2324357040.USD","BK4559","BK4585","BK4007","LU1983299246.USD","BK4557","BK4584","TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660077421","title":"TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660077421","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660077421?lang=en_us&edition=fundamental","pubTime":"2026-08-19 23:16","pubTimestamp":1787152563,"startTime":"0","endTime":"0","summary":"Shares in Teva Pharmaceutical Industries ($TEVA) were healthier today after a potential 50-year-long breakthrough treatment for Tourette syndrome m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/teva-stock-climbs-as-50-year-long-tourette-syndrome-drug-breakthrough-moves-closer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/teva-stock-climbs-as-50-year-long-tourette-syndrome-drug-breakthrough-moves-closer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4559","BK4566","LU2324357040.USD","BK4584","BK4585","BK4596","TEVA","BK4557","BK4588","LU1983299246.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660252964","title":"Femasys announces FDA approval of FemBloc modular premarket approval application","url":"https://stock-news.laohu8.com/highlight/detail?id=2660252964","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660252964?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:16","pubTimestamp":1787145413,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced that the FDA has approved the company’s modular premarket approval application pathway for FemBloc, its investigational no...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FEMY","PINK","TECB","IYH","LFSC","RSPH","TBXU","IEIH","MRNX","BK4588","MEDI","SYNB","BK4584","NVIB","IBB","GNMX","IDNA","BBP","LABU","XLVX","PSCH","FRTY","GDOC","BK4539","MRNY","BK4082","BMED","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660624425","title":"Teva Pharmaceuticals Says FDA Accepts Ecopipam Filing for Tourette Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2660624425","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660624425?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:10","pubTimestamp":1787145009,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries'  US affiliate Teva Pharmaceuticals said Wednesday the US Food and Drug Administration has accepted its new drug application for ecopipam to potentially treat children with Tourette syndrome.The regulator has set a target action date for late in Q1 of 2027, the company said.The application is supported by phase 2b and phase 3 data, which showed a reduction in tic severity and sustained efficacy, Teva said.Teva Pharmaceutical Industries shares were up 1.8% in premarket activity Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TEVA","BK4588","BK4007","BK4584","BK4566","BK4557","LU2324357040.USD","BK4596","LABU","BK4559","LU1983299246.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660425838","title":"Femasys Says FDA OKs Modular PMA Pathway for FemBloc Birth Control Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425838","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425838?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:00","pubTimestamp":1787144434,"startTime":"0","endTime":"0","summary":"Femasys says FDA OKs modular PMA pathway for FemBloc birth control deviceFDA cleared Femasys to use a modular PMA submission pathway for FemBloc, its investigational non-surgical permanent birth contr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL8HTqC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BN0W2T93.GBP","BK4585","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","SG9999014013.SGD","IE00BQXX3F31.USD","NDAQ","SG9999014005.SGD","LU0314104364.USD","FEMY","BK4539","BK4082","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4584","BK4112","SG9999014021.USD","LU2210150020.SGD","BCDF","BK4588","IE00BN0W2W23.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660803425","title":"Femasys - FDA Approves Modular Pma Pathway for Fembloc in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2660803425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660803425?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:00","pubTimestamp":1787144400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA61CLCY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","FEMY","BK4584","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660542580","title":"Femasys - Fembloc Approved for Marketing in Europe and Select International Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2660542580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660542580?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:00","pubTimestamp":1787144400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA61CLCY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4539","BK4082","FEMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660646700","title":"Daré Bioscience DARE-HPV Program Advances with Non-Dilutive US Government Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2660646700","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660646700?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:04","pubTimestamp":1787058290,"startTime":"0","endTime":"0","summary":"Daré Bioscience DARE-HPV program advances with non-dilutive US government fundingDaré Bioscience said its DARE-HPV program for persistent high-risk HPV is advancing with non-dilutive government fundin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL9RX6Np:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014013.SGD","BK4584","BK4585","BCDF","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014039.USD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","BK4007","BK4588","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","LU2210150020.SGD","DARE","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","SG9999014005.SGD","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660467776","title":"DarÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 over 50: Innovation” List","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467776","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660467776?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:02","pubTimestamp":1787058120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nTUA3YN9JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DARE","BK4007","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660460749","title":"DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List","url":"https://stock-news.laohu8.com/highlight/detail?id=2660460749","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660460749?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:02","pubTimestamp":1787058120,"startTime":"0","endTime":"0","summary":"National recognition comes as Daré Bioscience advances a multi-product women’s health strategy across commercialization, clinical development and first-in-category innovationSAN DIEGO, Aug.  18, 2026 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3346918/30757/en/dar%C3%A9-bioscience-ceo-sabrina-martucci-johnson-named-to-forbes-2026-50-over-50-innovation-list.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","DARE","LU0256331488.USD","LU0106261612.USD","DAR","LU0012050646.USD","BK4588","BK4007","LU0345780950.USD","LU2211817866.USD","LU1721429402.USD","BK4189","BK4584","FXG","LU2308191902.HKD","LU0630314457.HKD","BK4585","LU0345781412.USD","LU1803068623.USD","LU1721429741.USD","LU2380233275.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660432587","title":"Veru Chief Scientific Officer Gary Barnette Acquires $4,841.82 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660432587","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660432587?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:26","pubTimestamp":1786998405,"startTime":"0","endTime":"0","summary":"Veru Chief Scientific Officer Gary Barnette acquires $4,841.82 in common sharesVeru: Chief Scientific Officer K Gary Barnette bought 1,800 common shares at USD 2.69 each.Directly owned common shares r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL8W9cTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Veru Chief Scientific Officer Gary Barnette Acquires $4,841.82 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERU","BK4183","BK4584","BK4007","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660820480","title":"Daré Bioscience Prices USD 6 Million Registered Direct Offering at USD 1.37 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2660820480","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660820480?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:36","pubTimestamp":1786970176,"startTime":"0","endTime":"0","summary":"Daré Bioscience prices USD 6 million registered direct offering at USD 1.37 per shareDaré Bioscience priced a registered direct offering of 4,379,581 common shares, or pre-funded warrants, at USD 1.37","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL9P7kcp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","DARE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}